Abstract 71P
Background
Patient (pt) centricity and shared decision-making are now a global expectation and are dependent on pts receiving understandable information. The increasing number of targeted therapeutic options for those with mBC rely on the identification of biomarkers. This survey probed pts’ information experiences and understanding of relevant mBC biomarkers.
Methods
An online survey was distributed to pts with a self-reported diagnosis of mBC via ABC Global Alliance members. Survey questions captured pts’ recall of biomarker terminology, information seeking behavior, and barriers to learning about their diagnosis. Subgroup analyses were conducted by geography, disease history, and information preferences. Where applicable, statistical analysis was performed using Pearson’s Chi-square test.
Results
1064 pts from 6 continents completed the survey. Pt recall of biomarker terms used by healthcare professionals (HCPs) varied: ‘stage’ was the most frequently selected term, ‘subtype’ and ‘biomarker’ the least frequent. By region terms differed significantly, with North American pts displaying highest recall levels. 17% (n=55) of Western European pts reported that none of the terms were used. 67% (n=638) of pts felt they had learnt about and understood the type of breast cancer (BC) they have, with lower frequency observed among those diagnosed <1 year ago (p ≤ 0.01). Only 44% (n=415) of pts cited receiving all the information needed from HCPs. Pts sought information from several sources to learn more about their diagnosis, including the internet (70%, n=743), doctors (64%, n=676) and other people diagnosed with BC (45%, n=477). Those diagnosed <1 year ago were less likely to seek information from their doctor (p ≤ 0.05). 7% (n=75) of pts did not want more information, including 17% (n=29) of pts from Latin America. These pts were less likely to be told the importance of knowing their BC type by HCPs (p ≤ 0.05).
Conclusions
Results demonstrate a global need for improved HCP communication and pt education about mBC biomarkers, if pts are to make informed treatment decisions. Information should be tailored by source, delivery, and complexity based on pts’ diagnosis, cultural, and socioeconomic needs.
Editorial acknowledgement
Nisha Pillay, PhD, an employee of VML Health, London, provided editorial assistance for this abstract.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
L. Fallowfield: Financial Interests, Personal, Other, Honoraria or Grant funding: AstraZeneca, BeiGene, Norvatis, Eli Lilly, Roche, Gilead, Exact Sciences, Veracyte. A. Eniu: Financial Interests, Personal, Advisory Role: Gilead, Merck, Janssen, Novartis, Daiichi Sankyo (CH), Seagen, AstraZeneca, Eli Lilly; Financial Interests, Personal, Research Grant: Roche, Celltrion, Pfizer. R. Kaur: Financial Interests, Personal, Advisory Role, Honoraria for consultancy & advisory: Novartis, Roche, Pfizer, AstraZeneca. P. Hadland: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. R. Carolan: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. F. Cardoso: Financial Interests, Personal, Other, Consultancy: Amgen, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime, Astellas/Medivation, AstraZeneca, Celgene, Daiichi Sankyo, Eisai, GE Oncology, Genentech, GSK, IQVIA; Financial Interests, Institutional, Funding, Clinical Trials: Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb, Daiichi Sankyo, Eisai, Fresnius GmbH, Genentech, Gilead, GSK, Ipsen, Incyte, Nektar Therapeutics, Nerviano, Novartis, Macrogenics, Medigene, MedImmune, Merck, Millenium, Pfizer, Pierre-Fabre, Roche, Sanofi-Aventis, Sonus, Tesaro, Tigris, Wilex, Wyeth; Non-Financial Interests, Personal, Leadership Role, President: ABC Global Alliance and ABC Conference and Guidelines; Non-Financial Interests, Personal, Member, Committee Member: ESMO, ESO, EORTC-BCG, IBCSG, SOLTI, ASCO, AACR, EACR, SIS, ASPIC. All other authors have declared no conflicts of interest.